



EDELIRIS announces Research Collaboration with ROCHE

Lyon – April 4th, 2008 – EDELIRIS announced today that it has signed a multi-year research collaboration with ROCHE.

Under the terms of the agreement, Edelris will apply its medicinal chemistry expertise, in combination with its innovative strategies for the synthesis of natural product-like molecules, to design and produce advanced and exclusive high-profile compound series for Roche's early stages of Discovery.

"Edelris is very proud to enter such an agreement, and we look forward to providing ROCHE with some very promising compounds," commented Dr. Jean-Yves Ortholand, CEO of EDELIRIS. "With Edelris, Roche has identified expertise in the skills and high-level technology they were looking for. We have become one of Roche's major collaborators in this area due to our in-depth knowledge of Pharmaceutical Research needs, and this is an important recognition of the high level of innovation that has been demonstrated by Edelris over the past three years."

Financial terms of the collaboration were not disclosed.

About Edelris:

EDELIRIS is a MedChem-oriented Research & Service based company, dedicated to the design and production of innovative, therapeutically relevant, natural product-like screening compounds. Aiming at the acceleration of the hit/lead discovery process in pharmaceutical and biotech research organizations, EDELIRIS uses its track-proven chemistry and drug discovery expertise to provide novelty to its customers with exclusive or non-exclusive small molecules and with efficient hit/lead optimization capabilities.

Several customers from pharmaceutical and biotechnology companies worldwide have already recognized the value and specificity of Edelris offer, accessing either its experienced MedChem services or its innovative natural-mimetic Keymical Collections™.

Contact:

EDELIRIS s.a.s

Jean-Yves Ortholand, CEO

Phone: +33 (0)4 3756 1901

jean-yves.ortholand@edelris.com